Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Next Day Disclosure Return - Others
2025-04-08
Next Day Disclosure Returns - Share Buyback
2025-04-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
2025-04-07
Next Day Disclosure Returns - Share Buyback/Others
2025-04-03
Replay Link for Obesity Portfolio Webinar on April 2, 2025
2025-04-02
Next Day Disclosure Return - Others
2025-04-01
Inside Information - Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial With ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
2025-03-31
Annual Results Announcement for the Year Ended December 31, 2024 and Change in the Use of Proceeds
2025-03-26
Notice of Board Meeting
2025-03-13
Inside Information - Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide
2025-03-12

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1